NVDA
NVIDIA
-- 128.910 TSLA
Tesla
-- 440.130 MU
Micron Technology
-- 103.900 QUBT
Quantum Computing
-- 25.680 PLTR
Palantir
-- 71.510 
Novo Nordisk has launched the obesity drug "Wogoby" in China.
November 19, 2024, 9:43 AM GMT+9
Danish pharmaceutical giant novo-nordisk a/s announced on the 18th that it has launched the obesity treatment drug 'Ugobi' in china. It is estimated that over 180 million people in the country are obese.
With the entry of novo-nordisk a/s, competition intensifies with the american pharmaceutical giant eli lilly and co. While the company's obesity drug was approved in china in July, it has not yet been launched.
The release of Ugobi was first reported by the chinese broadcasting 第一財経 (YICAI), and novo-nordisk a/s's public relations officer confirmed this report to Reuters.With the entry of novo-nordisk a/s, competition intensifies with the american pharmaceutical giant eli lilly and co. While the company's obesity drug was approved in china in July, it has not yet been launched.
According to reports, the price for one month's starting dose of Ugobi is 1400 yuan (193.27 dollars) in china. The standard price in the usa for the same drug is about 1349 dollars per month.
Ugobi was approved for sale in china in June. Initially, it targets patients who are willing to self-fund for a once-weekly dose.
In China, Ugobi is not covered by public health insurance. The First Financial Report quoted an executive from Novo Nordisk as saying that the company is exploring ways to make Ugobi more affordable through private insurance, etc.
Ugobi was approved for sale in china in June. Initially, it targets patients who are willing to self-fund for a once-weekly dose.
In China, Ugobi is not covered by public health insurance. The First Financial Report quoted an executive from Novo Nordisk as saying that the company is exploring ways to make Ugobi more affordable through private insurance, etc.
Novo Nordisk launched Ugobi in the USA in 2021. The company's stock price has been at an all-time high due to strong revenue in the USA and 15 other countries where it was subsequently launched.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
綾のAYA : Isn't it expensive?
5年以内に社畜卒業 : It's amazing how japan, which can be used for insurance repayment depending on the conditions. It can be used for diabetes treatment with GLP-1 formulations, almost at the same patient's expense.